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Targeted next-generation sequencing <p>Combining next-generation sequencing with capture of sequences from a relevant subset of a transcriptome produces an enhanced  view of this subset</p>
Abstract
Targeted RNA-Seq combines next-generation sequencing with capture of sequences from a
relevant subset of a transcriptome. When testing by capturing sequences from a tumor cDNA
library by hybridization to oligonucleotide probes specific for 467 cancer-related genes, this
method showed high selectivity, improved mutation detection enabling discovery of novel chimeric
transcripts, and provided RNA expression data. Thus, targeted RNA-Seq produces an enhanced
view of the molecular state of a set of "high interest" genes.
Background
In recent years, a technologic revolution has shifted DNA
sequencing from traditional Sanger methods to "next-gener-
ation" sequencing (see review [1]). Applying these new
sequencing methods to cDNA libraries, termed RNA-Seq,
generates a wealth of information beyond that obtained from
sequencing genomic DNA (see review [2]). RNA-Seq provides
insights at multiple levels into the transcription of the
genome as it yields sequence, splicing, and expression-level
information leading to the identification of novel transcripts
[3,4] and sequence alterations. For research into somatic
mutations in cancer (for example, The Cancer Genome Atlas
[5-7]), this method has the advantage of enriching for
changes in coding sequences, which are more likely to affect
function, compared with sequencing genomic DNA. Chromo-
somal rearrangements, including translocations, are an
important class of mutations in cancer [8]. Although chromo-
somal rearrangements can be detected by next-generation
sequencing of genomic DNA [9,10], RNA-Seq is a powerful
tool to identify those rearrangements that lead to chimeric
transcripts and are more likely to have functional conse-
quences in cancer [3,11].
Despite these advantages of RNA-Seq, the complexity of the
transcriptome and the wide dynamic range of expression lev-
els render whole-transcriptome sequencing an expensive
proposition, particularly at the depth required to call muta-
tions and identify structural rearrangements or aberrant
splice forms in low-abundance mRNAs. Mortazavi and col-
leagues [12] reported that 40 million reads were required to
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provide onefold coverage of a transcriptome, whereas the
calling genotypes with high confidence may require coverage
levels of at least fivefold to 20-fold [13]. This magnitude of
coverage invariably results in vast oversampling of abundant
transcripts, which adversely affects the efficiency and overall
power of the approach.
Cost and efficiency considerations have prompted the emer-
gence of methods that allow "targeted" next-generation
sequencing. Two suitably high-throughput approaches to
enrich specific sequences from genomic DNA have been
developed: multiplexed molecular inversion probes (MIPs)
[14-16] and capture by hybridization to oligonucleotide
probes on microarrays [17-19] or in solution [20]. MIPs are
similar to PCR primers in that they enrich loci defined by two
flanking specific sequences. Thus, they are not appropriate
for the discovery of novel chromosomal rearrangements such
as translocations. By contrast, capture by hybridization can
enrich DNA fragments that extend beyond the probe
sequence, including sequences that are not contiguous in the
reference sequence. Solution hybrid selection is a capture
method that uses a complex mixture of RNA baits derived
from PCR-amplified oligodeoxynucleotides to select hybridiz-
ing sequences in a library of DNA fragments [20]. To date,
however, hybridization-based capture approaches have been
applied primarily to genomic DNA, typically for the purpose
of enriching exonic DNA of interest. Although targeted
sequencing of genomic DNA facilitates mutation-discovery/
profiling, it is unable to interrogate the myriad additional
genomic alterations affecting DNA and mRNA that are criti-
cal to tumor biology and therapeutic development.
In this study, we explore the feasibility and power of "targeted
RNA-Seq," the application of hybridization capture methods
to transcriptome analysis. When applied to 467 cancer-
related genes, this novel approach increased the coverage of
low-abundance transcripts to levels that enabled reliable
identification of sequence changes. In addition, this method
provided information about relative expression levels, facili-
tated the discovery of novel splice variants, and enabled
detection of novel fusion transcripts and isoforms thereof
that would otherwise have escaped detection. As such, this
method fills an important niche in cancer research, as well as
other areas of genomics, by generating all the multifaceted
genomic and gene-expression information in a single,
straightforward experiment.
Results
cDNA hybrid selection
To develop a targeted RNA-Seq method, we created a com-
plex pool of biotinylated oligonucleotide probes (baits) for
cancer-related transcripts and used them to capture cDNAs
from a library prepared for Illumina sequencing. We targeted
467 genes in total (887 distinct transcripts; Table S1 in Addi-
tional data file 1), representing the majority of all protein
tyrosine kinase genes, nuclear hormone-receptor genes, and
genes catalogued in the Cancer Gene Census [21]. Baits were
designed in a tiling fashion with minimal overlap to span the
entire protein-coding region of each transcript. To test the
method, a cDNA library for Illumina sequencing was con-
structed from the K-562 chronic myeloid leukemia (CML) cell
line. From an aliquot of this library, we selected cDNAs
hybridizing with these cancer cDNA baits. We used PCR to
regenerate a double-stranded DNA library that was
sequenced in a single lane on the Illumina Genome Analyzer
platform. To obtain a baseline for comparison, we also
sequenced the original unenriched cDNA library.
Sequence enrichment
Sequence analysis of the cDNA library after hybrid selection
demonstrates that nearly all the high-quality, aligning reads
derive from targeted genes. Approximately eight million
purity-filtered [13] 76-mer sequence reads were generated for
each cDNA library (before and after hybrid selection; Table
1). Reads were aligned to all curated RefSeq transcripts,
requiring a unique genomic locus of origin for each placement
(see Materials and methods). Hybrid selection resulted in a
huge increase in specificity, with 98% of aligned reads map-
ping to a target transcript, versus 5% before hybrid selection
(Table 1). As expected, the overall improvement in mean
sequence coverage of the target transcripts was greatest for
the protein-coding regions, increasing from 14.4× before
hybrid selection to 606.3× after hybrid selection--a 42-fold
difference (Figure 1a). The distribution in sequence coverage
for the 467 target genes is shown in Figure 1b. For instance,
only 62 (13%) genes achieve 20× sequence coverage before
hybrid selection, whereas an additional 234 genes for a total
of 296 (63%) genes are covered by at least 20× after hybrid
selection. Also of note, the number of genes detectable by at
least one read increases from 360 to 410 (77% to 88%). The
remaining 12% of genes are probably expressed at a very low
level or not at all in K-562.
This increase in sequence coverage also increased the sensi-
tivity for detecting sequence variants in these target genes. At
positions with sufficient sequence coverage, we identified
nonreference bases, including SNPs and candidate muta-
tions. Hybrid selection enabled us to identify 257 known
SNPs at high confidence (LOD > 5) in the coding sequences of
target genes, compared with only 76 before hybrid selection.
Similarly, we identified four novel variants before hybrid
selection and an additional 12 for a total of 16 after hybrid
selection (Table S2 in Additional data file 2). Thirteen (81%)
of the 16 were successfully validated by traditional Sanger
sequencing of PCR products amplified from K-562 genomic
DNA. By comparison, three (75%) of the four novel variants
detected before hybrid selection were validated.
We next asked whether the degree of enrichment for a target
g e n e  d e p e n d e d  o n  i t s  t r a n s c r i p t  a b u n d a n c e  b e f o r e  h y b r i d
selection. As shown in Figure 2, the sequence coveragehttp://genomebiology.com/2009/10/10/R115 Genome Biology 2009,     Volume 10, Issue 10, Article R115       Levin et al. R115.3
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observed after hybrid selection is well correlated with the
sequence coverage observed before hybrid selection, indicat-
ing that the relative abundance of cDNAs from targeted genes
was generally preserved. This result suggests that some
expression-profiling results can be obtained simultaneously
with information about sequence variants for genes targeted
by hybrid selection. The correlation (r2 = 0.71) is somewhat
lower than typically observed between technical replicates of
an RNA-Seq experiment [12], but comparable to the correla-
tion between different expression profiling methods (for
example, RNA-Seq and microarray hybridization) [22]. This
correlation improves if the analysis is limited to transcripts in
a narrower range of GC content: r2 = 0.78 for GC 0.4 to 0.6
(645 transcripts) and r2 = 0.87 for GC 0.45 to 0.55 (317 tran-
scripts), indicating some bias introduced by the hybrid selec-
tion or the additional round of PCR or both.
Increase in sequence coverage Figure 1
Increase in sequence coverage. (a) Mean sequence coverage by region. Transcript regions (5' UTR, CDS, 3' UTR) were divided into deciles, and the 
sequence coverage for each decile was averaged across all 887 target transcripts. Coverage is displayed for before hybrid selection (blue) and after hybrid 
selection (red). The average length of each region is 292, 2,136, and 1,729, respectively. (b) Distribution of sequence coverage for targeted genes. For each 
sequence-coverage threshold (x-axis), the fraction of 467 genes at or above that threshold is plotted (y-axis) for before hybrid selection (blue) and after 
hybrid selection (red).
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Table 1
Analysis of Illumina sequence in cDNA hybrid selection
Sequence filter criteria Beforea Aftera
Total purity-filtered reads 7,907,124 7,635,761
Aligned to all transcriptome 4,515,009 6,664,152
Unique in transcriptome 4,303,769 6,508,099
Mapping to 1 of 887 target transcripts 220,151 6,364,131
On-target specificity 5% 98%
aNumber of sequence reads before and after hybrid selection.
Preservation of expression levels of target transcripts in hybrid selection Figure 2
Preservation of expression levels of target transcripts in hybrid selection. 
For each target transcript, the sequence coverage of the coding region is 
plotted before and after hybrid selection.
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The overall enrichment in sequence coverage for the target
transcripts also enabled the identification of a greater
number of alternatively spliced isoforms of these genes. Con-
sidering all possible logical intragenic combinations of exons
annotated in RefSeq, 70,344 hypothetical splice junctions
exist for the 467 target genes, and 6,593 of these have been
annotated in RefSeq. The number of confirmed exon junc-
tions involving target genes increased from 2,958 before
hybrid selection to 4,720 after hybrid selection (Table S3 in
Additional data file 3). Of these confirmed junctions, 294 are
previously unannotated in RefSeq, involving 130 target
genes. Genes exhibiting alternative splicing in K-562 were
identified as described in Materials and methods. Hybrid
selection revealed at least 177 target genes to be alternatively
spliced, compared with 52 target genes before hybrid selec-
tion. Taken together, these results demonstrate the power of
targeted RNA-Seq to illuminate both SNPs and splicing vari-
ants in an efficient manner.
Fusion-transcript detection
Because chromosomal rearrangements have important roles
in cancer [8], we sought to determine whether cDNA hybrid
selection could provide enhanced evidence for this class of
mutations. Although K-562 has been the subject of numerous
studies, until recently only the BCR-ABL1  translocation,
which is extensively amplified [23], has been identified at the
nucleotide level. We searched our cDNA Illumina data for evi-
dence of gene fusions, or fusion transcripts composed of por-
tions of two distinct genes (see Materials and methods). In
brief, we nominated candidate fusions from 76-mer reads for
which the first 30 bases and the last 30 bases uniquely aligned
to separate genes, and then we searched all the reads again for
76-mers that were entirely consistent with a fusion between
these two genes (requiring at least 12 bases overlap with each
g e n e ) .  W e  d e t e c t e d  t w o  g e n e  f u s i o n s  i n  t h e  c D N A  l i b r a r y
before hybrid selection: BCR-ABL1 (13 reads) and NUP214-
XKR3 (9 reads). Both gene fusions were found at similar fre-
quencies in K-562 in a recently published RNA-Seq study [11].
After hybrid selection, BCR-ABL1  was implicated by 874
reads, and NUP214-XKR3 was implicated by 152 reads (Table
2 and Figure 3). Although NUP214  fusions have been
observed previously in tumors and other cell lines [11,24,25],
NUP214-XKR3 is of particular interest because it shows that
we can enrich for fusion transcripts for which only one of the
genes, NUP214, was directly targeted by the hybrid-selection
baits. The NUP214-XKR3  reads derive from one end of a
larger fragment, and the orientation of the reads indicates
that the cDNA fragments were composed mostly of NUP214
sequence (Table S4 in Additional data file 4). This bias in
sequence composition of fusion-transcript cDNA fragments
Sequences from NUP214-XKR3 fusion transcripts detected after hybrid selection Figure 3
Sequences from NUP214-XKR3 fusion transcripts detected after hybrid selection. After hybrid selection, 152 reads were aligned to the transcriptome and 
detected as NUP214-XKR3 fusions. From top to bottom, we observed 137, four, eight, and three reads for these transcripts. The NUP214 (exon 27) to 
XKR3 (exon 4) has a stop codon downstream (not shown). Only NUP214 (exon 29) to XKR3 (exon 4) retains an open reading frame downstream of the 
fusion. Before hybrid selection, eight reads were aligned to the transcriptome and detected as NUP214-XKR3 fusions; only the NUP214 (exon 29) to XKR3 
(exon 2) transcript was detected. Sequence from NUP214 DNA is shown as lower case, and from XKR3, as bold and upper case.
 
 
NUP214 (exon 29) XKR3 (exon 2)
NUP214 (exon 29) XKR3 (exon 3)
NUP214 (exon 29) XKR3 (exon 4)
NUP214 (exon 27) XKR3 (exon 4)
caacctctgggttcagcttttgccaagcttcagCACCCTGAGAATGGAGACAGTGTTTGAAGAGATGGATG
caacctctgggttcagcttttgccaagcttcagGTGTTTGCACACCGTTAGAAATTACCACAAATGGTTGAAAAATC
caacctctgggttcagcttttgccaagcttcagCATTGCTGATGACATTTTCCCTGTTATCAGTTACTTATGGGGC
attttctccatcaggCATTGCTGATGACATTTTCCCTGTTATCAGTTACTTATGGGGCCATTCGCTGCAATATACT
TSGFS C F QASAP STOP
TSGFS C F QASGV CTPLE T I T N G STOP
TSGFS C F QASALLMTFS L L SVTYG
FSPSG A I DDIFPVISYL G WH S L Q Y Thttp://genomebiology.com/2009/10/10/R115 Genome Biology 2009,     Volume 10, Issue 10, Article R115       Levin et al. R115.5
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is as expected because the baits target only the NUP214
sequence. Another important finding is that this method ena-
bled detection of three additional NUP214-XKR3  fusion-
transcript isoforms in 7.6 million reads (Figure 3 and Table 1)
that were not detected without hybrid selection nor in the
20.7 million reads in the recent K-562 RNA-Seq study [11]. All
four of the NUP214-XKR3 fusion transcripts were confirmed
by Sanger sequencing RT-PCR products (data not shown). It
is interesting to note that only one of the four NUP214-XKR3
fusions maintains an open reading frame downstream of the
fusion event (Figure 3). This fusion was not detected by
sequencing the cDNA library before hybrid selection nor in
the recent K-562 RNA-Seq study [11]. Understanding the
functional significance of these fusion transcripts is beyond
the scope of this study, but this work clearly demonstrates the
power of targeted RNA-Seq to detect them.
In addition to BCR-ABL1  and NUP214-XKR3, which were
both detected before hybrid selection, we identified four gene
fusions after hybrid selection that may have otherwise gone
undetected and were not found previously [11]. In each case,
only one of the two genes was specifically targeted by baits
(Table 2 and Table S4 in Additional data file 4). Three of the
four gene fusions involve the production of "read-through"
transcripts in which exons from separate, adjacent genes are
joined together in a single mRNA molecule. Read-through
transcripts have previously been discovered in cancer and
have been shown to contribute to tumorigenicity [3]. The
fourth novel gene fusion involves the previously annotated
SNHG3-RCC1 read-through transcript on chromosome 1 and
PICALM on chromosome 11. As with NUP214-XKR3, multi-
ple splice isoforms were detected for SNHG3-RCC1-PICALM,
and four of five of them were confirmed by sequencing RT-
PCR products (data not shown). Although these observations
are consistent with a single genomic translocation followed by
alternative splicing of the resulting RNA in both cases, it also
is possible that further amplifications and rearrangements at
this locus contributed to the multiple fusion transcripts
observed.
Discussion
In this study, we demonstrated that combining hybridization
capture of a cDNA library with Illumina sequencing provides
a robust and sensitive method to detect a wide range of DNA
and RNA sequence alterations present in cancer cells. First,
this method has a very high specificity, as 98% of the
sequence mapping to RefSeq aligns to targeted transcripts
after hybrid selection (Table 1). Second, this selectivity leads
to improved detection of SNPs (Figure 1), splice isoforms, and
fusion transcripts (Table 2) in the targeted transcripts.
Importantly, this property reduces the amount of sequencing,
and consequently costs, required to identify mutations and
other cancer-associated variants. Third, differences in tran-
script abundance are generally preserved after hybrid selec-
tion (Figure 2), likely because the baits are in molar excess
during the hybridization [20]. Similarly, preservation of
genomic copy-number alterations (that is, amplifications and
deletions) has been observed after hybrid selection of
genomic DNA in cell lines with well-characterized chromo-
somal aberrations (M.F.B. and L.A.G., unpublished data) and
in filter-based hybridization experiments [26]. Fourth, infor-
mation that reflects function, such as expression levels, alter-
native splicing, and RNA editing, can be obtained by RNA-
Seq directly from RNA input material rather than from
genomic DNA. Beyond RNA expression levels (Figure 2), it is
also possible to demonstrate that a particular fusion tran-
script is expressed, to identify fusion transcripts with partner
genes that are not in targeted baits, and even to show the rel-
ative abundance of different spliced fusion transcripts (Table
2 and Figure 3). Fifth, fusion transcripts due to trans-splicing
[27] would also be detected by this method, but not by
genomic sequencing, and could be distinguished from trans-
locations by validation experiments with genomic DNA. In
summary, by sequencing cDNA rather than genomic DNA, we
generated a richer view of the biologic state of this cell line.
Recent studies that used MIPs to select for sequences subject
to RNA editing [28] or to analyze allele-specific expression
[29] provide additional examples of how targeted RNA-Seq
can enhance our understanding of the molecular state of the
transcriptome. Finally, this method is easily scalable to larger
numbers of samples and genes.
Our targeted RNA-Seq method provides a direct and powerful
approach to discover and characterize translocations and to
study their prevalence in all types of cancer [8], including
solid tumors, which is an area of active research [3,4].
Although the role of translocations in leukemias and sarco-
mas is well established, we were able to identify novel fusion
transcripts in the well-studied K-562 CML cell line (Table 2).
By enriching for cDNA sequences from genes of known rele-
vance to cancer, targeted RNA-Seq makes possible the identi-
fication of translocations for any number of targeted genes in
a single experiment. In addition, oncogenes often have multi-
ple translocation partners [8], and this method provides an
effective tool to identify new partners for genes previously
identified in translocations, because only one of the two
Table 2
Hybrid selection-enhanced detection of fusion transcripts
5' Gene 5' Chr. 3' Gene 3' Chr. Beforea Aftera
BCR 22 ABL1 91 38 7 4
NUP214b 9 XKR3b, c 22 9 152
SNHG3-RCC1b, c 1 PICALMb 11 1 39
PRIM1c, d 12 NACAb, d 12 0 22
NCKIPSD d 3 CELSR3c, d 30 5
SLC29A1c, d 6 HSP90AB1 d 60 2
aNumber of sequence reads before and after hybrid selection. bFusion 
transcript reads identified from more than one exon in this gene. cNot 
included in hybrid selection bait genes. dNot previously annotated, 
read-through transcripts between adjacent genes.http://genomebiology.com/2009/10/10/R115 Genome Biology 2009,     Volume 10, Issue 10, Article R115       Levin et al. R115.6
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translocated genes must be present in the hybrid-selection
baits. This method is able to recover fusion transcripts in
which incomplete matches to baits exist, probably because
baits adjacent to the bait whose sequence contains the break-
point enable this recovery and enrichment. This may be pos-
sible because the cDNA library inserts are 290 to 390 bp,
which is larger than the 170-base baits.
It is interesting to compare the efficacy of targeted RNA-Seq
to enhance detection of low-abundance transcripts with that
of cDNA library normalization. Normalization is better suited
for discovery of sequence changes in transcripts not known to
be associated with a particular biologic question. By contrast,
targeted RNA-Seq is ideal for increasing coverage for a subset
of "high interest" transcripts. Further, unlike normalization,
targeted RNA-Seq preserves expression-level information
(Figure 2). In addition, targeted RNA-Seq can achieve higher
increases in coverage for a subset of targeted transcripts,
depending on the number of unique baits designed. If cover-
age of lower abundance transcripts is a priority in a given
experiment, information about transcript abundance can be
used during bait design to focus on those transcripts with tar-
geted RNA-Seq. Conventional normalization methods
[30,31] are unlikely to achieve easily the approximately 30-
fold enrichment for most low-abundance transcripts
observed in our targeted RNA-Seq experiments (Figure 1;
JZL., XA, unpublished results).
Conclusions
By combining hybridization capture of cDNAs and next-gen-
eration sequencing, targeted RNA-Seq provides an efficient
and cost-effective means to analyze a specific subset of a tran-
scriptome simultaneously for mutations, structural altera-
tions, and expression levels. This method overcomes the
limitations of conventional RNA-Seq that requires signifi-
cantly greater sequencing depth to generate sufficient cover-
age of low-abundance transcripts. It also circumvents certain
limitations of targeted genomic DNA sequencing, in which
detection of chromosomal rearrangements may be challeng-
ing (and analysis of mRNA effects is impossible). In a single
experiment, targeted RNA-Seq provides a wealth of qualita-
tive as well as quantitative information that cannot be
obtained by any single other method. Targeted RNA-Seq is
therefore a powerful and convenient new approach that is
well suited for a wide range of large-scale tumor-profiling
studies in many clinical or research settings.
Materials and methods
Illumina library construction and sequencing
A K-562 cDNA library (insert size of 290 to 390 bp) for Illu-
mina sequencing was constructed from a 500 ng aliquot of
double-stranded cDNA prepared from 3 μg polyA+  RNA
(Ambion, Austin, TX USA) primed with 0.3 μg random hex-
amers (Invitrogen, Carlsbad, CA USA), as described previ-
ously [22], except (a) no RNase inhibitor was used, (b) low-
intensity shearing was performed for 5 seconds rather than 4
seconds, and (c) PCR primers were removed with 1.8× vol-
umes of AMPure beads (Agencourt Bioscience Corporation,
Beverly, MA USA). We used 14 PCR cycles to generate the
library before hybrid selection and an additional 18 cycles
afterward with the same PCR conditions. Single reads of 76
bases were generated on an Illumina Genome Analyzer II.
The raw unaligned Illumina sequences in SRF (sequence-
read format) are available at [32].
Bait design and synthesis
We designed 11,566 bait sequences (Table S5 in Additional
data file 5) targeting the coding sequence of 887 transcripts of
467 genes described in the NCBI RefSeq database. The Ref-
Seq file used contained 45,376 transcript sequences from all
NM and XM human transcripts (downloaded from [33] on
June 23, 2008). Each bait was composed of 170 bases match-
ing the transcript sequence it was intended to enrich. Baits
were tiled across the coding region of each transcript, from 5'
to 3', such that all coding bases were covered by at least one
bait and that overlap between baits was minimized and dis-
tributed evenly among all baits. The median and mean over-
laps between adjacent baits were five and seven bases,
respectively. Where genes existed with multiple splice vari-
ants, baits were designed for each splice variant independ-
ently, so that 9,913 unique baits were designed. The baits
were synthesized by Agilent Technologies (Santa Clara, CA
USA) on a custom 55,000 spot array. To fully use the array,
the 11,566 baits were replicated so that at least two copies of
each oligonucleotide were ordered, plus two copies of the
reverse complement of each oligonucleotide. Oligonucle-
otides and their reverse complements give rise to the same
PCR products. Thus, although sense and antisense oligonu-
cleotides were chemically synthesized, only sense RNA baits
were present in the hybridization.
Hybrid selection
Five hundred nanograms of the K-562 cDNA Illumina library
was selected as described previously [20], except that the
MEGAshortscript T7 Kit (Ambion) was used for the bait prep-
aration.
Sequence alignment and coverage
Purity-filtered [13] 76-mer reads were aligned to all curated
protein-coding transcripts in RefSeq (downloaded from [33]
o n  M a r c h  1 ,  2 0 0 9 )  a l l o w i n g  u p  t o  f o u r  m i s m a t c h e s ,  a n d
mapped back to their genomic coordinates in the reference
human genome (hg18), preserving splice junctions. Align-
ments were performed by using the ImperfectLookupTable
(ILT) tool of the ARACHNE genome assembly suite [34].
Reads were considered informative if all placements to Ref-
Seq transcripts originated from a unique genomic locus, and
the next-best placement contained at least three additional
mismatches. Sequence coverage was determined separately
for 5' UTRs, coding sequences (CDS), and 3' UTRs.http://genomebiology.com/2009/10/10/R115 Genome Biology 2009,     Volume 10, Issue 10, Article R115       Levin et al. R115.7
Genome Biology 2009, 10:R115
Sequence variant identification
To eliminate false positives in calling mutations, reads align-
ing to RefSeq transcripts were also aligned directly to the
genome, and uniqueness was required in both the transcrip-
tome and the genome. Each position was assigned a LOD
score indicating the likely accuracy of the call, according to
the observed sequence coverage, allele distribution, and ref-
erence base [20]. Of 1,085,748 bases in the coding sequence
of targeted genes, 297,693 bases exhibited LOD greater than
5 before hybrid selection, and 724,211 bases exhibited LOD
greater than 5 after hybrid selection. Bases that disagreed
with the reference genome were classified as known SNPs if
present in dbSNP [35] (build 129) or as novel variants. Novel
variants were discarded if they occurred within five bases of
another novel variant (to compensate for alignment artifacts
produced by indels), if they were observed on Illumina reads
in only one orientation, or if they fell within segmental dupli-
cations [36]. The remaining novel variants were considered
high confidence and submitted for validation (see later).
Splice isoform identification
To catalog the exon junctions detected by RNA-Seq, we cre-
ated a database of all hypothetical intragenic exon junctions
involving RefSeq genes. Each 76-mer read was aligned to this
new reference-sequence database in the same manner as
described earlier. Exon junctions were "confirmed" in K-562
if they harbored at least two distinct 76-mer reads mapping to
the junction with, at most, four mismatches but with at least
10 mismatches with their best placement on the genome.
Those genes with at least two confirmed exon junctions that
overlapped each other (for example, one upstream exon
joined to two downstream exons, two upstream exons joined
to one downstream exon, or alternating exons) were consid-
ered to be alternatively spliced.
Fusion transcript identification
To identify candidate gene fusions from individual 76-mer
reads, the first 30 and last 30 bases were separately aligned to
all curated protein-coding transcripts in RefSeq (allowing up
to two mismatches). Reads for which both ends mapped to
separate genes were flagged for further analysis. Gene pairs
implicated by at least two distinct reads (for which the orien-
tation was consistent with a gene fusion) were nominated as
candidate fusions. The entire set of 76-mer reads was then
searched for instances joining any exon of the upstream gene
to any exon of the downstream gene across the full 76 bases,
requiring at least 12 bases overlap with each gene. To call con-
fidently a gene pair as a fusion event, we required at least two
distinct instances that could not be placed anywhere else in
the transcriptome or the genome. The criteria used are con-
servative to avoid false-positive fusion transcript alignments;
additional fusion transcripts may be present, but not detecta-
ble with these alignment parameters and coverage levels.
Validation of sequence alterations
Novel SNPs called by RNA-Seq were validated by traditional
bidirectional Sanger sequencing of PCR products that had
been amplified from 20 ng of K-562 genomic DNA by 35 PCR
cycles with Herculase Hotstart DNA polymerase (Stratagene,
La Jolla, CA, USA).
For NUP214-XKR3 and SNHG3-RCC1-PICALM fusion tran-
scripts, confirmation was attempted by Sanger sequencing of
RT-PCR products. First-strand cDNA was synthesized from
K-562 mRNA with random hexamers (Invitrogen) or gene-
specific primers (Eurofins MWG Operon, Huntsville, AL,
USA) as described earlier. For random priming, 1 μg mRNA
and 1.5 μg random hexamers were used, and for gene-specific
priming, 500 ng mRNA and 2 pmol gene-specific primers
were used. The cDNA was purified by using 1.8× volume of
Agencourt AMPure PCR Purification kit. Fusion transcript-
containing cDNAs were then amplified by 30 to 40 PCR cycles
by using 1/50 of the purified first-strand cDNA, 25 pmol for-
ward and reverse gene-specific primers, 100 μmol Betaine
(Sigma-Aldrich, St. Louis, MO USA), and Phusion Master Mix
with GC Buffer (New England BioLabs, Ipswich, MA, USA) in
a 50 μl volume. PCR products were gel purified from a 10%
TBE Criterion Gel (BioRad, Hercules, CA, USA). Gel slices
were excised, crushed, and eluted with 250 μl 0.3 M NaCl for
more than 4 hours followed by ethanol precipitation. The
purified PCR products were sequenced as described earlier
and compared with junctions identified by Illumina sequenc-
ing. All primer sequences are available on request.
Abbreviations
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SRF: sequence read format.
Authors' contributions
JZL and MFB wrote the article. XA, AM, AG, CN, and LAG
assisted in editing the article. MFB chose the targeted genes,
and TF designed the baits. XA prepared the Illumina cDNA
libraries. PR and AM performed the hybrid selection. MFB
and JZL analyzed the sequence data. XA and AG confirmed
fusion transcripts and SNPs, respectively. JZL, CN, LAG, and
AG conceived and directed the research.
Additional data files
The following additional data are available with the online
version of this article: a table listing the bait gene names and
transcript accession numbers (Additional data file 1), a table
listing novel SNPs (Additional data file 2), a table listing
splice junctions (Additional data file 3), a table listing Illu-
mina reads from fusion transcripts (Additional data file 4),
and a table listing the bait sequences (Additional data file 5).
Additional data file 1 Bait gene names and transcript accession numbers Bait gene names and transcript accession numbers Click here for file Additional data file 2 Novel SNPs Novel SNPs Click here for file Additional data file 3 Splice junctions Splice junctions Click here for file Additional data file 4 Illumina reads from fusion transcripts Illumina reads from fusion transcripts Click here for file Additional data file 5 Bait sequences Bait sequences Click here for filehttp://genomebiology.com/2009/10/10/R115 Genome Biology 2009,     Volume 10, Issue 10, Article R115       Levin et al. R115.8
Genome Biology 2009, 10:R115
Acknowledgements
We thank the staff of the Broad Institute Genome Sequencing Platform for
generating sequencing data. We are grateful for help from Terrance Shea
and Sarah Young with SNP calling. This work was supported by National
Human Genome Research Institute grant HG03067-05, the Starr Cancer
Consortium (L.A.G.), and National Institutes of Health grant
DP2OD002750 (LAG).
References
1. Holt RA, Jones SJ: The new paradigm of flow cell sequencing.
Genome Res 2008, 18:839-846.
2. Wang Z, Gerstein M, Snyder M: RNA-Seq: a revolutionary tool
for transcriptomics.  Nat Rev Genet 2009, 10:57-63.
3. Maher CA, Kumar-Sinha C, Cao X, Kalyana-Sundaram S, Han B, Jing
X, Sam L, Barrette T, Palanisamy N, Chinnaiyan AM: Transcriptome
sequencing to detect gene fusions in cancer.  Nature 2009,
458:97-101.
4. Zhao Q, Caballero OL, Levy S, Stevenson BJ, Iseli C, de Souza SJ,
Galante PA, Busam D, Leversha MA, Chadalavada K, Rogers YH, Ven-
ter JC, Simpson AJ, Strausberg RL: Transcriptome-guided charac-
terization of genomic rearrangements in a breast cancer cell
line.  Proc Natl Acad Sci USA 2009, 106:1886-1891.
5. McLendon R, Friedman A, Bigner D, Van Meir EG, Brat D, Mastro-
gianakis GM, Olson JJ, Mikkelsen T, Lehman N, Aldape K, Yung WK,
Bogler O, Weinstein JN, VandenBerg S, Berger M, Prados M, Muzny
D, Morgan M, Scherer S, Sabo A, Nazareth L, Lewis L, Hall O, Zhu Y,
Ren Y, Alvi O, Yao J, Hawes A, Jhangiani S, Fowler G, et al.: Compre-
hensive genomic characterization defines human glioblast-
oma genes and core pathways.  Nature 2008, 455:1061-1068.
6. Collins FS, Barker AD: Mapping the cancer genome: pinpoint-
ing the genes involved in cancer will help chart a new course
across the complex landscape of human malignancies.  Sci Am
2007, 296:50-57.
7. The Cancer Genome Atlas   [http://cancergenome.nih.gov/]
8. Rabbitts TH: Commonality but diversity in cancer gene
fusions.  Cell 2009, 137:391-395.
9. Campbell PJ, Stephens PJ, Pleasance ED, O'Meara S, Li H, Santarius T,
Stebbings LA, Leroy C, Edkins S, Hardy C, Teague JW, Menzies A,
Goodhead I, Turner DJ, Clee CM, Quail MA, Cox A, Brown C,
Durbin R, Hurles ME, Edwards PA, Bignell GR, Stratton MR, Futreal
PA: Identification of somatically acquired rearrangements in
cancer using genome-wide massively parallel paired-end
sequencing.  Nat Genet 2008, 40:722-729.
10. Hampton OA, Den Hollander P, Miller CA, Delgado DA, Li J, Coarfa
C, Harris RA, Richards S, Scherer SE, Muzny DM, Gibbs RA, Lee AV,
Milosavljevic A: A sequence-level map of chromosomal break-
points in the MCF-7 breast cancer cell line yields insights into
the evolution of a cancer genome.  Genome Res 2009,
19:167-177.
11. Maher CA, Palanisamy N, Brenner JC, Cao X, Kalyana-Sundaram S,
Luo S, Khrebtukova I, Barrette TR, Grasso C, Yu J, Lonigro RJ,
Schroth G, Kumar-Sinha C, Chinnaiyan AM: Chimeric transcript
discovery by paired-end transcriptome sequencing.  Proc Natl
Acad Sci USA 2009, 106:12353-12358.
12. Mortazavi A, Williams BA, McCue K, Schaeffer L, Wold B: Mapping
and quantifying mammalian transcriptomes by RNA-Seq.
Nat Methods 2008, 5:621-628.
13. Bentley DR, Balasubramanian S, Swerdlow HP, Smith GP, Milton J,
Brown CG, Hall KP, Evers DJ, Barnes CL, Bignell HR, Boutell JM, Bry-
ant J, Carter RJ, Keira Cheetham R, Cox AJ, Ellis DJ, Flatbush MR,
Gormley NA, Humphray SJ, Irving LJ, Karbelashvili MS, Kirk SM, Li H,
Liu X, Maisinger KS, Murray LJ, Obradovic B, Ost T, Parkinson ML,
Pratt MR, et al.: Accurate whole human genome sequencing
using reversible terminator chemistry.  Nature 2008,
456:53-59.
14. Porreca GJ, Zhang K, Li JB, Xie B, Austin D, Vassallo SL, LeProust EM,
Peck BJ, Emig CJ, Dahl F, Gao Y, Church GM, Shendure J: Multiplex
amplification of large sets of human exons.  Nat Methods 2007,
4:931-936.
15. Krishnakumar S, Zheng J, Wilhelmy J, Faham M, Mindrinos M, Davis
R: A comprehensive assay for targeted multiplex amplifica-
tion of human DNA sequences.  Proc Natl Acad Sci USA 2008,
105:9296-9301.
16. Turner EH, Lee C, Ng SB, Nickerson DA, Shendure J: Massively par-
allel exon capture and library-free resequencing across 16
genomes.  Nat Methods 2009, 6:315-316.
17. Okou DT, Steinberg KM, Middle C, Cutler DJ, Albert TJ, Zwick ME:
Microarray-based genomic selection for high-throughput
resequencing.  Nat Methods 2007, 4:907-909.
18. Albert TJ, Molla MN, Muzny DM, Nazareth L, Wheeler D, Song X,
Richmond TA, Middle CM, Rodesch MJ, Packard CJ, Weinstock GM,
Gibbs RA: Direct selection of human genomic loci by micro-
array hybridization.  Nat Methods 2007, 4:903-905.
19. Hodges E, Xuan Z, Balija V, Kramer M, Molla MN, Smith SW, Middle
CM, Rodesch MJ, Albert TJ, Hannon GJ, McCombie WR: Genome-
wide in situ exon capture for selective resequencing.  Nat
Genet 2007, 39:1522-1527.
20. Gnirke A, Melnikov A, Maguire J, Rogov P, LeProust EM, Brockman
W, Fennell T, Giannoukos G, Fisher S, Russ C, Gabriel S, Jaffe DB,
Lander ES, Nusbaum C: Solution hybrid selection with ultra-
long oligonucleotides for massively parallel targeted
sequencing.  Nat Biotechnol 2009, 27:182-189.
21. Futreal PA, Coin L, Marshall M, Down T, Hubbard T, Wooster R,
Rahman N, Stratton MR: A census of human cancer genes.  Nat
Rev Cancer 2004, 4:177-183.
22. Yassour M, Kaplan T, Fraser HB, Levin JZ, Pfiffner J, Adiconis X,
Schroth G, Luo S, Khrebtukova I, Gnirke A, Nusbaum C, Thompson
DA, Friedman N, Regev A: Ab initio construction of a eukaryotic
transcriptome by massively parallel mRNA sequencing.  Proc
Natl Acad Sci USA 2009, 106:3264-3269.
23. Wu SQ, Voelkerding KV, Sabatini L, Chen XR, Huang J, Meisner LF:
Extensive amplification of bcr/abl fusion genes clustered on
three marker chromosomes in human leukemic cell line K-
562.  Leukemia 1995, 9:858-862.
24. Graux C, Cools J, Melotte C, Quentmeier H, Ferrando A, Levine R,
Vermeesch JR, Stul M, Dutta B, Boeckx N, Bosly A, Heimann P, Uyt-
tebroeck A, Mentens N, Somers R, MacLeod RA, Drexler HG, Look
AT, Gilliland DG, Michaux L, Vandenberghe P, Wlodarska I, Marynen
P, Hagemeijer A: Fusion of NUP214 to ABL1 on amplified epi-
somes in T-cell acute lymphoblastic leukemia.  Nat Genet 2004,
36:1084-1089.
25. Quentmeier H, Schneider B, Rohrs S, Romani J, Zaborski M, Macleod
RA, Drexler HG: SET-NUP214 fusion in acute myeloid leuke-
mia- and T-cell acute lymphoblastic leukemia-derived cell
lines.  J Hematol Oncol 2009, 2:3.
26. Herman DS, Hovingh GK, Iartchouk O, Rehm HL, Kucherlapati R,
Seidman JG, Seidman CE: Filter-based hybridization capture of
subgenomes enables resequencing and copy-number detec-
tion.  Nat Methods 2009, 6:507-510.
27. Li H, Wang J, Mor G, Sklar J: A neoplastic gene fusion mimics
trans-splicing of RNAs in normal human cells.  Science 2008,
321:1357-1361.
28. Li JB, Levanon EY, Yoon JK, Aach J, Xie B, Leproust E, Zhang K, Gao
Y, Church GM: Genome-wide identification of human RNA
editing sites by parallel DNA capturing and sequencing.  Sci-
ence 2009, 324:1210-1213.
29. Zhang K, Li JB, Gao Y, Egli D, Xie B, Deng J, Li Z, Lee JH, Aach J, Lep-
roust EM, Eggan K, Church GM: Digital RNA allelotyping reveals
tissue-specific and allele-specific gene expression in human.
Nat Methods 2009, 6:613-618.
30. Soares MB, Bonaldo MF, Jelene P, Su L, Lawton L, Efstratiadis A: Con-
struction and characterization of a normalized cDNA
library.  Proc Natl Acad Sci USA 1994, 91:9228-9232.
31. Zhulidov PA, Bogdanova EA, Shcheglov AS, Vagner LL, Khaspekov
GL, Kozhemyako VB, Matz MV, Meleshkevitch E, Moroz LL, Lukyanov
SA, Shagin DA: Simple cDNA normalization using kamchatka
crab duplex-specific nuclease.  Nucleic Acids Res 2004, 32:e37.
32. Broad Institute Targeted RNA-Seq Sequence Data   [http://
www.broad.mit.edu/annotation/cDNA/cDNA.html]
33. NCBI RefSeq Human mRNA FTP site   [ftp://ftp.ncbi.nih.gov/
refseq/H_sapiens/mRNA_Prot/]
34. Jaffe DB, Butler J, Gnerre S, Mauceli E, Lindblad-Toh K, Mesirov JP,
Zody MC, Lander ES: Whole-genome sequence assembly for
mammalian genomes: Arachne 2.  Genome Res 2003, 13:91-96.
35. Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM,
Sirotkin K: dbSNP: the NCBI database of genetic variation.
Nucleic Acids Res 2001, 29:308-311.
36. Bailey JA, Yavor AM, Massa HF, Trask BJ, Eichler EE: Segmental
duplications: organization and impact within the current
human genome project assembly.  Genome Res 2001,
11:1005-1017.